TLSI logo

TRISALUS LIFE SCIENCES INC

TLSINASDAQ
🏆 #3482 by market capEarnings Nov 10US Equity
$3.87▼ $0.06 (−1.53%)
Market closed · at close
🔔
Track TLSI
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.5%
7d▲ 8.4%
14d▲ 6.0%
30d▼ 9.8%
ytd▼ 44.4%
1y▼ 16.6%
🏦Market Cap
$238M
Small Cap
📈Revenue Growth (YoY)
25.3%
High Growth
📊Gross Margin
85.8%
High
💵FCF Margin
—
⚖️P/S Ratio
5.4x
Fair
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$3.83 – $4.01
52-Week Range
$2.20 – $7.95
Volume (shares)
4,308
Avg Volume (shares)
—
Shares Outstanding
61.6M
Next Earnings
2026-11-10

Fundamentals Snapshot

Annual Revenue
$45M
Last Q Revenue
$11M
P/E Ratio
—
P/S Ratio
5.4x
EPS (TTM)
$-0.59
Dividend Yield
—
Dilution (1yr)
+76.8%
TLSI logo

TRISALUS LIFE SCIENCES INC

TLSI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$45M▲ +53.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
84.6%▼ −1.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$27M▼ −25.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$19M▼ −54.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
46.8M▲ +76.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$14M▲ +$1M YoY
StockOtter · stockotter.space

About TRISALUS LIFE SCIENCES INC

TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
11 analysts
Strong Buy2
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.